Bryn Mawr Trust Advisors LLC Makes New $613,000 Investment in Boston Scientific Corporation $BSX

Bryn Mawr Trust Advisors LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,278 shares of the medical equipment provider’s stock, valued at approximately $613,000.

Several other hedge funds also recently modified their holdings of the business. Steph & Co. acquired a new position in shares of Boston Scientific in the 3rd quarter valued at approximately $25,000. Financial Consulate Inc. bought a new stake in Boston Scientific in the 3rd quarter valued at about $25,000. FWL Investment Management LLC bought a new position in Boston Scientific in the 2nd quarter valued at about $26,000. Kilter Group LLC bought a new position in shares of Boston Scientific in the second quarter worth about $30,000. Finally, Princeton Global Asset Management LLC bought a new stake in shares of Boston Scientific during the second quarter worth about $32,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $93.58 on Friday. The firm has a market capitalization of $138.72 billion, a PE ratio of 50.04, a price-to-earnings-growth ratio of 1.64 and a beta of 0.67. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50. The firm has a 50-day moving average price of $95.21 and a 200-day moving average price of $99.49. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47.

Insider Buying and Selling at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 80,204 shares of company stock worth $7,998,563. 0.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

BSX has been the topic of a number of research reports. Royal Bank Of Canada boosted their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Canaccord Genuity Group decreased their target price on Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Truist Financial dropped their target price on Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Finally, Citigroup restated a “buy” rating on shares of Boston Scientific in a report on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $123.89.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.